Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Factors related to the utilization of digital adherence technologies in tuberculosis care: A qualitative study among adults in DS-TB treatment, health care providers and other key actors in Tanzania.
Gonçalves Tasca B, Mganga A, Leung CL, Shilugu L, Pell C, Onjare B, Luvanda N, Mleoh L, de Groot L, van Kalmthout K, Fielding K, Jerene D. Gonçalves Tasca B, et al. Among authors: mleoh l. PLOS Glob Public Health. 2024 Aug 8;4(8):e0002795. doi: 10.1371/journal.pgph.0002795. eCollection 2024. PLOS Glob Public Health. 2024. PMID: 39116120 Free PMC article.
Feasibility and acceptability of the smart pillbox and medication label with differentiated care to support person-centered tuberculosis care among ASCENT trial participants - A multicountry study.
Tadesse AW, Mganga A, Dube TN, Alacapa J, van Kalmthout K, Letta T, Mleoh L, Garfin AMC, Maraba N, Charalambous S, Foster N, Jerene D, Fielding KL. Tadesse AW, et al. Among authors: mleoh l. Front Public Health. 2024 Feb 20;12:1327971. doi: 10.3389/fpubh.2024.1327971. eCollection 2024. Front Public Health. 2024. PMID: 38444445 Free PMC article. Clinical Trial.
Effectiveness of digital adherence technologies in improving tuberculosis treatment outcomes in four countries: a pragmatic cluster randomised trial protocol.
Jerene D, Levy J, van Kalmthout K, Rest JV, McQuaid CF, Quaife M, Charalambous S, Gamazina K, Garfin AMC, Mleoh L, Terleieva Y, Bogdanov A, Maraba N, Fielding K. Jerene D, et al. Among authors: mleoh l. BMJ Open. 2023 Mar 14;13(3):e068685. doi: 10.1136/bmjopen-2022-068685. BMJ Open. 2023. PMID: 36918242 Free PMC article.
Implementation of the 'Removed Injectable modified Short-course regimens for EXpert Multidrug Resistant Tuberculosis' (RISE study) in Tanzania: a protocol for a mixed-methods process evaluation.
Kalolo A, Lalashowi J, Pamba D, Shayo PJ, Gitige C, Mvungi H, Ntagazwa W, Lekule I, Kisonga R, Mleoh L, John J, Kapologwe NA, Mutayoba B, Matechi E, Mpagama SG, Ntinginya NE. Kalolo A, et al. Among authors: mleoh l. BMJ Open. 2022 May 24;12(5):e054434. doi: 10.1136/bmjopen-2021-054434. BMJ Open. 2022. PMID: 35613774 Free PMC article.
Gridlock from Diagnosis to Treatment of Multidrug-Resistant Tuberculosis (MDR-TB) in Tanzania: Illuminating Potential Factors for Possible Intervention.
Liyoyo AA, Heysell SK, Kisonga RM, Lyimo JJ, Mleoh LJ, Mutayoba BK, Lekule IA, Mmbaga BT, Kibiki GS, Mpagama SG. Liyoyo AA, et al. Among authors: mleoh lj. East Afr Health Res J. 2017;1(1):31-39. doi: 10.24248/EAHRJ-D-16-00330. Epub 2017 Mar 1. East Afr Health Res J. 2017. PMID: 34308156 Free PMC article.
Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
Semvua HH, Mtabho CM, Fillekes Q, van den Boogaard J, Kisonga RM, Mleoh L, Ndaro A, Kisanga ER, van der Ven A, Aarnoutse RE, Kibiki GS, Boeree MJ, Burger DM. Semvua HH, et al. Among authors: mleoh l. Antivir Ther. 2013;18(1):105-13. doi: 10.3851/IMP2413. Epub 2012 Oct 5. Antivir Ther. 2013. PMID: 23043067 Clinical Trial.